Tailwinds' Take: ITUS has a potentially game-changing diagnostic here. Dr. Kumar's comments about benign studies are quite foreshadowing. We can expect to hear more about this in the future. Also note the multi-billion valuations on liquid biopsy diagnostic companies;...
This afternoon Anixa (ANIX) filed a mixed-shelf offering of up to $100M in securities. Included in this was a sales agreement with B. Riley for up to $50M in equity sales; essentially an ATM has been put in place. This...
I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences are nearly as terrible as a real war, but in the figurative sense, August left...
SAN JOSE, CA -- (Marketwired) -- 09/21/17 -- ITUS Corporation (NASDAQ: ITUS) today provides a corporate update before its Annual Meeting of Stockholders to be held on September 22, 2017. ITUS's wholly owned subsidiary Anixa Diagnostics, recently renewed its research agreement with...
Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the coming year. The list is comprised of potential macroeconomic events that have, according to Mr. Wien,...
Tailwinds' Take: although this is a minor delay from previous (best case) guidance, it is still fabulous news that Anixa expects to have a CAR-T drug in humans next summer. We expect to see the stock at much higher...
Tailwinds' Take: to date, all data on C-Chek has been positive and there's no reason to expect anything different if they have been accepted as an abstract at ASCO-SITC. We believe that ITUS' novel cancer detection platform could be...
Tailwinds' Take: more positive data just before they meet with the FDA. Important notes from the data include potential "Phase 0" detection and the possibility that Cchek can be used for ongoing maintenance of breast cancer survivors. While the...
On Thursday January 24th, Anixa Biosciences held an investor update call. In the preview to the call, management had talked about 2019 being a "transformative" year for the Company. Based on their conference call, if they deliver on their...
In recent weeks, Anixa has met with the FDA regarding their CAR-T therapy and has now scheduled a discussion around Cchek for early December. These are important events as the FDA will review data submitted before even agreeing to...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.